Videos
Advertisement
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, shares her hopes for the new year.
Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease.
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
The CLL12 trial included patients with treatment-naive, asymptomatic, early-stage chronic lymphocytic leukemia.
Lisa Hwa, APRN, CNP, DNP, MS, discusses her work with the ASH Medical Educators Institute and her conference experience.
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Richard Newcomb, MD, shares insights from his ASH 2024 presentation and explains why nurses play a major role in outcomes.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
Kirk R. Schultz, MD, FCAHS, explains that multiple strategies for GVHD prevention and preemption are under investigation.
Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib.
Piyanuch Kongtim, MD, PhD, shares insights from work she presented at the 2024 ASH Annual Meeting.
Samantha Shenoy, NP, speaks about her experience at the meeting and key highlights in multiple myeloma research.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains key takeaways from her myeloma research at ASH 2024.
Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps.
Chronic GVHD is less frequent in children than in adults, but its frequency has come down much more significantly in adults.
Noah Merin, MD, PhD, explains how the GVHD prophylaxis method has changed outcomes and shares nursing implications at ASH.
A researcher who will present on patient-reported outcomes and GVHD outcomes discusses the importance of the meeting.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.